Literature DB >> 1369033

Recombinant human insulin.

M R Ladisch1, K L Kohlmann.   

Abstract

Insulin is a well-characterized peptide that can be produced by recombinant DNA technology for human therapeutic use. A brief overview of insulin production from both traditional mammalian pancreatic extraction and recombinant bacterial and yeast systems is presented, and detection techniques, including electrophoresis, are reviewed. Analytical systems for insulin separation are principally based on reversed-phase chromatography, which resolves the deamidation product(s) (desamido insulin) of insulin, proinsulin, and insulin. Process-scale separation is a multistep process and includes ion exchange, reversed-phase, and size exclusion chromatography. Advantages and/or disadvantages of various separation approaches, as described by the numerous literature references on insulin purification, are presented.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1369033     DOI: 10.1021/bp00018a001

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  14 in total

Review 1.  The pharmacology of regenerative medicine.

Authors:  George J Christ; Justin M Saul; Mark E Furth; Karl-Erik Andersson
Journal:  Pharmacol Rev       Date:  2013-07-01       Impact factor: 25.468

2.  Chemically Precise Glycoengineering Improves Human Insulin.

Authors:  Xiaoyang Guan; Patrick K Chaffey; Xiuli Wei; Daniel R Gulbranson; Yuan Ruan; Xinfeng Wang; Yaohao Li; Yan Ouyang; Liqun Chen; Chen Zeng; Theo N Koelsch; Amy H Tran; Wei Liang; Jingshi Shen; Zhongping Tan
Journal:  ACS Chem Biol       Date:  2017-12-01       Impact factor: 5.100

3.  Heterologous expression of a papain-like protease inhibitor (SnuCalCpI17) in the E. coli and its mode of inhibition.

Authors:  Chang Woo Kwon; Bokyong Chung; Sang-Ho Yoo; Pahn-Shick Chang
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-24       Impact factor: 4.813

Review 4.  The emergence of biosimilar insulin preparations--a cause for concern?

Authors:  David R Owens; Wolfgang Landgraf; Andrea Schmidt; Reinhard G Bretzel; Martin K Kuhlmann
Journal:  Diabetes Technol Ther       Date:  2012-10-09       Impact factor: 6.118

Review 5.  Equivalent Recombinant Human Insulin Preparations and their Place in Therapy.

Authors:  Juergen Sandow; Wolfgang Landgraf; Reinhard Becker; Gerhard Seipke
Journal:  Eur Endocrinol       Date:  2015-04-11

6.  Aptamers for pharmaceuticals and their application in environmental analytics.

Authors:  Beate Strehlitz; Christine Reinemann; Soeren Linkorn; Regina Stoltenburg
Journal:  Bioanal Rev       Date:  2011-12-17

7.  Characterization of the Interaction Between the Small Regulatory Peptide SgrT and the EIICBGlc of the Glucose-Phosphotransferase System of E. coli K-12.

Authors:  Anne Kosfeld; Knut Jahreis
Journal:  Metabolites       Date:  2012-10-16

8.  Prediction of Escherichia coli expression performance in microtiter plates by analyzing only the temporal development of scattered light during culture.

Authors:  Tobias Ladner; Martina Mühlmann; Andreas Schulte; Georg Wandrey; Jochen Büchs
Journal:  J Biol Eng       Date:  2017-07-03       Impact factor: 4.355

Review 9.  Downstream processing of recombinant human insulin and its analogues production from E. coli inclusion bodies.

Authors:  Yin Yin Siew; Wei Zhang
Journal:  Bioresour Bioprocess       Date:  2021-07-27

Review 10.  Recombinant Human Insulins - Clinical Efficacy and Safety in Diabetes Therapy.

Authors:  Wolfgang Landgraf; Juergen Sandow
Journal:  Eur Endocrinol       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.